Diabetes
| Type 2 diabetes
Diabetes
Type 2 diabetes

Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial

book_2 Source: Diabetes Care. 2021;44(6):1334-43.
calendar_today Published on Medfyle: September 2021
import_contacts 7 min
headphones 4 min

In this medfyle

Dapagliflozin drives major adjustments in energy metabolism.

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Expert commentary

Leigh Perreault, MD, FACE, FACP

Associate Professor of Medicine
Division of Endocrinology, Metabolism and Diabetes
Affiliate, Center for Global Health
University of Colorado Anschutz Medical Campus
Associate Professor of Epidemiology and Biostatistics
Colorado School of Public Health

About this Medfyle
Read more arrow_downward Hide arrow_upward

This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in Diabetes Care®, an official journal of the American Diabetes Association®, and is published in coordination with Sheridan. This MedFyle was created by GlobalPort (International) Limited with permission from the American Diabetes Association; neither Sheridan nor the American Diabetes Association takes any responsibility for its accuracy or for the use of any content therein by those reading or downloading such content.

The summary content was prepared by Marie Farrow for Medfyle, reviewed & approved by Leigh Perreault, MD, FACE, FACP

Original article:
Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial. Yvo J.M. Op den Kamp, Marlies de Ligt, Bas Dautzenberg, Esther Kornips, Russell Esterline, Matthijs K.C. Hesselink, Joris Hoeks, Vera B. Schrauwen-Hinderling, Bas Havekes, Jan Oscarsson, Esther Phielix, Patrick Schrauwen. Diabetes Care.2021;44(6)1334-1343.

The authors of the original article had no part in the creation of the summary.

 

All Medfyle content, summaries, expert commentaries and slides are owned by GlobalPort (International) Limited. The original journal articles are an exclusive copyright of the American Diabetes Association.

 

This activity is supported by an educational grant from Lilly.

Expert Insights
This activity is supported by an educational grant from Lilly.

Feedback